Myriad Genetics (MYGN) announced that its board has appointed Sam Raha, the company’s current COO, as president and CEO and as a member of the board, effective April 30. Raha will replace Paul Diaz, who is stepping down to join private equity firm Cressey & Company as a managing partner. Diaz will continue to serve the company as a consultant to Raha and the board for another year. The company also announced that Mark Verratti, Myriad’s current CCO will be promoted to COO concurrent with Raha’s appointment. A search for a new CCO is already underway.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics sees FY25 adjusted EPS 7c-11c, consensus 6c
- Myriad Genetics reports Q4 adjusted EPS 3c, consensus 3c
- Myriad Genetics sees Q1 adjusted EPS (8c)-(4c), consensus (2c)
- Myriad Genetics partners with PATHOMIQ for AI tech platform
- MYGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?